Topics
- The concept of risk-sharing to accelerate the market access
- Developing an effective strategy to succeed in country-specific negotiations for price approval and granting of reimbursement
- Dealing with the increasing complexity and uncertainty in current pricing & reimbursement environment
- Critical insights into HTAs & their role in assessments of new drugs
- Make market access an integral part of the company & incorporate market access into the entire drug’s life cycle
- Cost-effectiveness measures & the impact on the industry
- The role of HTAs
- How can interaction between regulators and payers facilitate access to orphan drugs?
The 8th Annual Pricing, Reimbursement & Market Access in Pharma 2013 brings together Vice Presidents, Senior Vice Presidents, Global Heads, Senior Executives, Directors, Heads, Managers and Senior Managers of: Reimbursement, Pricing, Commercial Pricing Pricing Strategists, Market Access, Outcomes Research, Health Economics, Governmental Affairs, Regulatory Affairs, Public Policy Directors, Public Affairs, Governmental bodies, Operations and Regulatory bodies.
